ABSTRACT
Objective To investigate the clinical effect of budesonide/formoterol single inhaler combined with tiotropium bromide in stable chronic obstructive pulmonary disease (COPD).Methods 80 cases of patients with stable COPD in China Aviation Industrial Xi'an Hospital from May 2014 to May 2016 were divided into observation group and control group,40 cases in each group.Patients in the control group were treated with budesonide/formoterol single inhaler,and in the observation group were treated with budesonide/formoterol single inhaler combined with tiotropium bromide.Compared the pulmonary function,life quality,serum levels of matrix metalloproteinases 9 (MMP-9) and interleukin 6 (IL-6),drug adverse reaction during the treatment and exacerbations episodes within the next six months.Results After treatment,the FEV1,FEV1/FVC,FEV1％ of two groups were significantly higher than before treatment (P ＜ 0.05),and in the observation group were significantly higher than that in control group (P ＜ 0.05).SGRQ scores,serum levels of MMP-9 and IL-6 of two groups were significantly lower than before treatment (P ＜ 0.05),and these indexes in the observation group were significantly lower than that in control group (P ＜ 0.05).The differences in the adverse reaction rate of two groups has no significant,the number of acute exacerbation in observation group were significantly lower than that of control group (P ＜ 0.05).Conclusion Budesonide/formoterol single inhaler combined with tiotropium bromide has remarkable clinical effect in stable COPD,and can effectively improve the pulmonary function,life quality,reduce the number of acute exacerbation,and reduce the serum levels of MMP-9,IL-6.
ABSTRACT
Objective To compare the efficacy between budesonide/formoterol single inhaler therapy and budesonide inhaler plus formoterol inhaler in children with bronchial asthma.Methods In randomized, open, parallel-group trial, 80 cases of children with bronchial asthma in children asthma center of Children's Hospital of Hebei Province were divided into B/F group ( budesonide/formoterol single inhaler therapy ) and B +F group (budesonide inhaler plus formoterol inhaler), 40 cases in each group.All patients in B/F group inspired budesonide formoterol sing inspirator [80μg (budesonide)/4.5μg(formoterol)/snuff], and all patients in B+F group inspired budesonide(100μg/snuff) and formoterol(4.5μg/snuff), 1 snuff/time, respectively, both groups were treated with 2 times/d,12 weeks.The visual analog scale(VAS), lung function as forced expiratory volume in one second(FEV1)%, peak expiratory flow(PEF) and clinical symptoms were investigated.Results Compared with B+F group in the same time period, PEF% and FEV1%on the 12th week were higher, VAS score on the 4th, 8th and 12th week were lower, symptoms scores on 8th and 12th were lower in B/F group, respectively(P<0.05).Conclusion The efficacy of budesonide/formoterol single inhaler therapy is better than that of budesonide inhaler plus formoterol inhaler in children with bronchial asthma, which is more convenience and has a better compliance.